RenovoRx Announces FY25 Net Loss Widening, Expects Phase III TIGeR-PaC Completion by Mid-2026
ByAinvest
Tuesday, Mar 31, 2026 2:46 am ET1min read
RNXT--
RenovoRx reported a wider net loss of $11.2mln for FY25, despite revenue growth to $1.12mln, driven by RenovoCath sales. The firm expects to complete enrolment for its Phase III TIGeR-PaC trial in mid-2026 and anticipates final data in 2027. RenovoRx also commercialises its TAMP technology and FDA-cleared RenovoCath as a stand-alone device, with an estimated initial total addressable market of $400mln in peak annual US sales.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet